Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety

　　Tarlatamab-Imdelltra,a DLL3/CD3-targeting bispecific T cell engager,represents a paradigm shift in solid tumor treatment by harnessing immune cell activation.However,its unique mechanism also triggers distinct immune-related adverse events(irAEs),requiring specialized management distinct from chemotherapy or traditional targeted therapies.

　　Key Adverse Events and Management Strategies

　　1.Cytokine Release Syndrome(CRS):The most common and characteristic toxicity,presenting as fever,chills,hypotension,and systemic inflammation.Management is graded:

　　●Mild(Grade 1):Symptomatic support(e.g.,antipyretics,hydration)with close monitoring.

　　●Moderate to Severe(≥Grade 2):Pause treatment,administer corticosteroids or IL-6 receptor antagonists(e.g.,tocilizumab),and adjust protocols under medical supervision.

　　2.Neurologic Toxicity(ICANS-like Symptoms):Includes confusion,speech impairment,attention deficits,or cognitive changes.Requires continuous neurologic assessment:

　　●Immediately suspend therapy upon symptom onset;severe cases necessitate neurological consultation and corticosteroid use.

　　3.Other Common Reactions:Fatigue,anemia,appetite loss,or increased infection risk are typically reversible.Managed through routine monitoring(e.g.,blood counts,inflammatory markers)and supportive care(e.g.,nutrition support,infection prophylaxis).

　　Core Management Principles

　　●Step-Up Dosing and Inpatient Monitoring:Initiate treatment with escalating doses under hospital supervision to mitigate initial immune activation and CRS risk.

　　●Dynamic Surveillance:Prioritize vital sign monitoring,cytokine profiling,and neurological symptom tracking for early intervention.

　　●Efficacy-Risk Balance:Given the correlation between adverse events and immune activation,treatment requires personalized dose adjustments or pauses to optimize outcomes.

　　Conclusion:Tarlatamab safety hinges on"precision modulation of immune activation"rather than symptom suppression alone.Through graded interventions,real-time monitoring,and individualized adjustments,clinicians can maximize therapeutic benefits while ensuring patient safety.